News

Half Yearly Report and Accounts

HALF YEARLY REPORT AND ACCOUNTS   February 28, 2018.​ Melbourne, Australia. Rhinomed (ASX:RNO or “the Company) releases its half yearly report and accounts. Read a full copy of the report here.

Rhinomed​ to Present at International Investor Conferences

RHINOMED​ ​TO PRESENT AT INTERNATIONAL INVESTOR CONFERENCES March 5, 2018.​ Melbourne, Australia. Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise it will exhibit and present at two major investor conferences in the USA and the UK in March. Read a full copy of the announcement here.

Rhinomed​ ​Change in Executive Remuneration

March 2, 2018.​ Melbourne, Australia.Rhinomed (ASX:RNO or “the Company) engaged Crichton and Associates, remuneration consultants to review its remuneration policies and make recommendations on the Company’s remuneration levels based on the market conditions and expectations. Read a full copy of the announcement here.

Rhinomed​ ​Completes AUD $3.6M Capital Raise

Rhinomed Limited (ASX: RNO or “the Company”) a leading sleep and nasal respiratory technology company has successfully undertaken an AUD$3.6 million placement to institutional and sophisticated private investors at $0.15 per share. Read a full copy of the announcement here.

RHINOMED​ ​TO​ ​DISTRIBUTE​ ​MUTE​ ​IN​ ​TAIWAN

September 14, 2017.​ Melbourne, Australia.Rhinomed (ASX:RNO) is pleased to announce a distribution agreement with Brojaw Inc., to begin distributing snoring and nasal breathing product Mute into the Taiwanese market. Read a full copy of the announcement here.

Amcal and Guardian Core Range Mute Australia Wide

Respiratory technology company Rhinomed (ASX:RNO) is pleased to announce that it has been advised by Sigma Healthcare that Mute sleep technology will form part of the 2017 core range for the Amcal and Guardian pharmacy brands. This adds to Rhinomed’s existing Sigma relationship which saw Discount Drug Stores stock Mute, meaning the majority of Sigma … Read more